Scienture (SCNX) said Tuesday the US Food and Drug Administration approved its new drug application for Arbli, an oral suspension formulation of hypertension drug losartan potassium.
The company said Arbli is indicated for hypertension in patients older than 6 years old, stroke risk reduction in patients with hypertension and left ventricular hypertrophy, and diabetic nephropathy in certain patients with type 2 diabetes.
The company also said the product has two patents and is expected to be listed in the FDA's Orange Book.
Scienture said it plans to launch Arbli in the US in Q3.
Shares of the company were up more than 24% in recent Tuesday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。